ID   1308-mel
AC   CVCL_A1DQ
SY   1308-MEL
DR   Wikidata; Q102113418
RX   PubMed=8027550;
RX   PubMed=9670966;
CC   From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*11,24 (PubMed=9670966).
CC   Derived from site: Metastatic; Not specified.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 10-09-24; Version: 5
//
RX   PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225;
RA   Marincola, Francesco M.
RA   Shamamian, Peter
RA   Alexander, Richard B.
RA   Gnarra, James R.
RA   Turetskaya, Regina L.
RA   Nedospasov, Sergei Arturovich
RA   Simonis, Toni B.
RA   Taubenberger, Jeffery Karl
RA   Yannelli, John R.
RA   Mixon, Arnold
RA   Restifo, Nicholas P.
RA   Herlyn, Meenhard
RA   Rosenberg, Steven A.
RT   "Loss of HLA haplotype and B locus down-regulation in melanoma cell
RT   lines.";
RL   J. Immunol. 153:1225-1237(1994).
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti, Maria P.
RA   Kim, Christina J.
RA   Lee, Kang-Hun
RA   Roden, Matthew
RA   Cormier, Janice N.
RA   Panelli, Monica C.
RA   Parker, Kenneth K.
RA   Marincola, Francesco M.
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//